Investor Alert: GPM Reminds Investors of the March 7 Deadline in the Class Action Lawsuit Against Agile Therapeutics,
Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the March 7, 2017 deadline to file a lead
plaintiff motion in the class action filed by GPM on behalf of a class (the “Class”) of investors who purchased Agile Therapeutics,
Inc. (“Agile” or the “Company”) (NASDAQ: AGRX) securities between March 9, 2016 and January 3, 2017, inclusive (the “Class Period”). Agile
investors have until March 7, 2017 to file a lead plaintiff motion.
The complaint filed in this lawsuit alleges that throughout the Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.
Specifically, Defendants failed to disclose: (1) that the Twirla contraceptive patch had an efficacy rating falling below peer
group standards; (2) that over half of patients in its “Secure” Phase 3 Study discontinued the study early; (3) that the Twirla
patch therefore allegedly had a slight chance of FDA approval; and (4) that, as a result of the foregoing, Defendants’ statements
about Agile’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On January 3, 2017, Agile disclosed statistical information pertaining to its Phase 3 SECURE study analyzing the Company’s
combined hormonal contraceptive patch Twirla. The study, which was initiated at the request of the FDA, comes after the FDA
rejected Agile's initial marketing application back in 2013. The Company cited "positive top-line results" in the study, yet
reported that an efficacy measure that failed to meet the standard set by other approved contraceptive patches. Additionally,
51.4% of subjects opted to discontinue the study.
On this news, Agile stock fell nearly 64% during intraday trading on January 4, 2017.
If you purchased or otherwise acquired Agile securities during the Class Period you may move the Court no later
than March 7, 2017 to request appointment as lead plaintiff. To be a member of the class you need not take any
action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish
to learn more about this action, or if you have any questions concerning this announcement or your rights or interests
with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and
number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170224005002/en/